ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1636191
This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 46 articles
The Prognostic Impact of TRMT6 on Ovarian Cancer Progression and Immune Microenvironment
Provisionally accepted
- Hebei General Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: This study investigates the impact of the m1A regulator TRMT6 on prognosis and the tumor microenvironment in ovarian cancer. Methods: An analysis of the TCGA database was conducted, supplemented by validation from clinical specimens (13 paired samples), to systematically evaluate the expression characteristics of 10 m1A regulators. The prognostic value was assessed using the Kaplan-Meier Plotter database and Cox regression analysis. Additionally, immunohistochemistry and the Log-rank test were employed to validate the impact of TRMT6 on the prognosis and clinicopathological characteristics of ovarian cancer patients. The ssGSEA algorithm and CIBERSORT were utilized to analyze the influence of TRMT6 on the tumor immune microenvironment. We performed single-gene differential analysis of TRMT6 in the TCGA ovarian cancer database using the DESeq2 package and constructed a ceRNA network. Results: Three m1A regulators (TRMT10C, TRMT6, YTHDF1) were significantly overexpressed in cancer tissues (p < 0.01). Specifically, among these, TRMT6 and YTHDF1 were significantly associated with lower progression-free survival and overall survival (OS) (p < 0.01). Notably, TRMT6 emerged as an independent prognostic factor for predicting poor overall survival (HR = 2.74; 95% CI, 1.13 - 6.65; P = 0.026). TRMT6 expression had a significant correlation with the pathological stage. Furthermore, TRMT6 expression exhibited a significant negative correlation with eleven tumor-infiltrating immune cell types, including cytotoxic cells (p < 0.01). We also found that in ovarian cancer tissues with high expression of TRMT6, the enrichment scores of T cells gamma delta (p < 0.01) and Mast cells activated (p < 0.05) were significantly lower than those in tissues with low expression. HPSE2 has the most interaction nodes among mRNAs, hsa-miR-17-5p among miRNAs, and Lnc SNHG14 among lncRNAs in the ceRNA 2 network. Conclusion: The findings suggest that the m1A regulator TRMT6 may drive ovarian cancer progression by promoting immune escape.
Keywords: m1A regulator1, TRMT62, Ovarian cancer3, poor prognosis4, tumor cells immune escape5
Received: 27 May 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Zhao, Wang, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jing Zhao, 1029423895@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.